Lp-PLA2: a New Marker of Vascular Risk
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to measure Lp-PLA2 levels. C-reactive protein (CRP), another inflammatory mediator, appears to be a biomarker for coronary disease (MH Shishehbor et al, Cleve Clin J Med 2003; 70:634). The role of Lp-PLA2 testing in determining cardiovascular risk is less clear....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Lp-PLA2: a New Marker of Vascular Risk
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1167
Article Code: 1167b
Date: October 13, 2003
Volume: 45
Pages: 83-84
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1167
Article Code: 1167b
Date: October 13, 2003
Volume: 45
Pages: 83-84
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)